Twinbeech Capital LP Insmed Inc Transaction History

Twinbeech Capital LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$16.26 - $21.73 $4.04 Million - $5.4 Million	248,667 New	248,667 $4.24 Million
Q3 2022 Nov 14, 2022	BUY	$20.88 - $28.21 $2.21 Million - $2.99 Million	106,031 New	106,031 $2.28 Million
Q2 2022 Aug 15, 2022	SELL	$17.07 - $25.71 $580,823 - $874,808	-34,026 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$20.42 - $28.13 $694,810 - $957,151	34,026 New	34,026 $800,000
Q1 2021 May 17, 2021	SELL	$32.28 - $44.3 $510,379 - $700,427	-15,811 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$31.45 - $40.54 $497,255 - $640,977	15,811 New	15,811 $526,000
Q1 2020 May 15, 2020	SELL	$13.63 - $33.98 $197,757 - $493,015	-14,509 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$16.12 - $24.98 $233,885 - $362,434	14,509 New	14,509 $346,000

467

182M

2.27M

3.33M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $9.48B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.